intravenous infusions

Summary

Summary: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.

Top Publications

  1. ncbi FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
  2. ncbi Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Dennis M Black
    University of California, San Francisco, San Francisco, CA 94107, USA
    N Engl J Med 356:1809-22. 2007
  3. ncbi Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    Thomas J Walsh
    National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 346:225-34. 2002
  4. ncbi Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
    P A Vasey
    CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Cancer Res 5:83-94. 1999
  5. ncbi Effect of volume loading with 1 liter intravenous infusions of 0.9% saline, 4% succinylated gelatine (Gelofusine) and 6% hydroxyethyl starch (Voluven) on blood volume and endocrine responses: a randomized, three-way crossover study in healthy volunteers
    Dileep N Lobo
    Division of Gastrointestinal Surgery, Nottingham Digestive Diseases Centre NIHR Biomedical Research Unit, Nottingham University Hospitals, Queen s Medical Centre, Nottingham, UK
    Crit Care Med 38:464-70. 2010
  6. ncbi The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis
    Ross L Paterson
    Academic Unit of Anaesthesia and Intensive Care, University of Aberdeen, Scotland, UK
    Crit Care Med 31:2574-8. 2003
  7. ncbi Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
    Weijing Sun
    University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 23:4897-904. 2005
  8. ncbi A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
  9. ncbi A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)
    Joseph Muenzer
    University of North Carolina, Department of Pediatrics, CB 7487, Chapel Hill, NC 27599 7487, USA
    Mol Genet Metab 90:329-37. 2007
  10. ncbi Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study
    G W Albers
    Stanford Stroke Center, Stanford University Medical Center, Palo Alto, Calif 94304 1705, USA
    JAMA 283:1145-50. 2000

Detail Information

Publications343 found, 100 shown here

  1. ncbi FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
    ..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)...
  2. ncbi Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Dennis M Black
    University of California, San Francisco, San Francisco, CA 94107, USA
    N Engl J Med 356:1809-22. 2007
    ..We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period...
  3. ncbi Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    Thomas J Walsh
    National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 346:225-34. 2002
    ..Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative...
  4. ncbi Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
    P A Vasey
    CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Cancer Res 5:83-94. 1999
    ..The recommended Phase II dose is 280 mg/m2 every 3 weeks. Studies are planned in colorectal, NSCLC, and breast cancer patients...
  5. ncbi Effect of volume loading with 1 liter intravenous infusions of 0.9% saline, 4% succinylated gelatine (Gelofusine) and 6% hydroxyethyl starch (Voluven) on blood volume and endocrine responses: a randomized, three-way crossover study in healthy volunteers
    Dileep N Lobo
    Division of Gastrointestinal Surgery, Nottingham Digestive Diseases Centre NIHR Biomedical Research Unit, Nottingham University Hospitals, Queen s Medical Centre, Nottingham, UK
    Crit Care Med 38:464-70. 2010
    ..9% saline, Gelofusine (4% succinylated gelatin in 0.7% saline, weight-average molecular weight 30 kD), and Voluven (6% hydroxyethyl starch in 0.9% saline, weight-average molecular weight 130 kD) in healthy volunteers...
  6. ncbi The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis
    Ross L Paterson
    Academic Unit of Anaesthesia and Intensive Care, University of Aberdeen, Scotland, UK
    Crit Care Med 31:2574-8. 2003
    ..In this pilot study we investigated the effect of N-acetylcysteine on nuclear factor-kappa B activation and circulating cytokine and adhesion molecules in patients with sepsis...
  7. ncbi Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
    Weijing Sun
    University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 23:4897-904. 2005
    ..Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain...
  8. ncbi A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
    ..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease...
  9. ncbi A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)
    Joseph Muenzer
    University of North Carolina, Department of Pediatrics, CB 7487, Chapel Hill, NC 27599 7487, USA
    Mol Genet Metab 90:329-37. 2007
    ..To evaluate the safety and explore the efficacy of idursulfase (recombinant human iduronate-2-sulfatase) treatment for mucopolysaccharidosis II (MPS II)...
  10. ncbi Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study
    G W Albers
    Stanford Stroke Center, Stanford University Medical Center, Palo Alto, Calif 94304 1705, USA
    JAMA 283:1145-50. 2000
    ..Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration...
  11. ncbi Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine and Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Oncologist 13:725-32. 2008
    ..Considering the heterogeneity of infusion reactions, clinicians need to recognize the underlying nature of these events in order to identify patients at risk as well as provide optimal prophylactic measures and management of symptoms...
  12. ncbi Population pharmacokinetics of propofol: a multicenter study
    J Schuttler
    Department of Anesthesiology, Friedrich Alexander University of Erlangen Nuremberg, Germany
    Anesthesiology 92:727-38. 2000
    ..This method requires accurate knowledge of pharmacokinetics, including the effects of age and weight. The authors performed a multicenter population analysis to quantitate the effects of covariates...
  13. ncbi Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial
    Norio Kohno
    Department of Surgery, Hyogo Medical Center for Adults, 13 70 Kitaojicho Akashi 673 0021, Japan
    J Clin Oncol 23:3314-21. 2005
    ..To investigate the efficacy and safety of zoledronic acid for the treatment of bone metastases from breast cancer...
  14. ncbi Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Can
    W V Kern
    Sektion Infektiologie und Klinische Immunologie, Medizinische Universitätsklinik und Poliklinik, Ulm, Germany
    N Engl J Med 341:312-8. 1999
    ..If orally administered empirical therapy is as effective as intravenous therapy, it would offer advantages such as improved quality of life and lower cost...
  15. pmc Methodology of the Interventional Management of Stroke III Trial
    Pooja Khatri
    Department of Neurology, University of Cincinnati, 231 Albert Sabin Way ML 0525, Cincinnati, OH 45267 0525, USA
    Int J Stroke 3:130-7. 2008
    ..a.) approach to recanalization may be more effective than standard i.v. rt-PA (Activase) alone for moderate-to-large National Institutes of Health Stroke Scale (NIHSS>or=10) strokes, and with a similar safety profile...
  16. ncbi Nicotine and nonnicotine factors in cigarette addiction
    Jed E Rose
    Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, 2424 Erwin Road, Suite 201, Durham, NC 27705, USA
    Psychopharmacology (Berl) 184:274-85. 2006
    ..These include constituents that provide reinforcing sensory stimulation, components that minimize excessive irritation from inhaled nicotine and other pharmacologically active compounds in cigarette smoke...
  17. ncbi Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    ..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
  18. ncbi Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
    Michele Reni
    Department of Radiochemotherapy, S Raffaele H Scientific Institute, Milan, Italy
    Lancet Oncol 6:369-76. 2005
    ..We aimed to assess whether a four-drug regimen could improve 4 month progression-free survival compared with gemcitabine alone...
  19. ncbi Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
    F M Muggia
    Department of Radiology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
    J Clin Oncol 15:987-93. 1997
    ..Liposomal doxorubicin was selected as a result of its superior activity against ovarian cancer xenografts relative to free doxorubicin and activity in refractory ovarian cancer patients that was noted during the phase I study...
  20. ncbi Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    Kennedy R Lees
    Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
    Lancet 375:1695-703. 2010
    ..We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis...
  21. ncbi Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:2267-72. 2001
    ..The objective of the study was to assess the tolerance and efficiency of weekly vinorelbine in metastatic breast carcinoma after failure with taxanes...
  22. ncbi Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock
    Matthias W A Angstwurm
    Medizinische Klinik Innenstadt, Ludwig Maximilians Universitat Munchen, Munich, Germany
    Crit Care Med 35:118-26. 2007
    ..We postulated that high-dose supplementation of sodium-selenite would improve the outcome of patients with severe sepsis and septic shock...
  23. ncbi Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers
    Anand Kumar
    Division of Cardiovascular Disease and Critical Care Medicine, Rush Presbyterian St Luke s Medical Center, 1653 West Congress Parkway, Chicago, IL 60612 3833, USA
    Intensive Care Med 30:1361-9. 2004
    ..Characterize the normal human cardiovascular response to large volume infusion of normal saline...
  24. ncbi Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects
    Esben Thyssen Vestergaard
    Medical Department M Endocrinology and Diabetes, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    Am J Physiol Endocrinol Metab 292:E1829-36. 2007
    ....
  25. ncbi Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial
    Maurie Markman
    The Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 21:2460-5. 2003
    ....
  26. ncbi Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study
    M Y Kirov
    Department of Anesthesiology, Northern State Medical University, Arkhangelsk, Russia
    Crit Care Med 29:1860-7. 2001
    ..Infusion of MB appears to have no significant adverse effects on the selected organ function variables...
  27. ncbi A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group
    J R Wingard
    Division of Hematology, University of Florida College of Medicine, Gainesville, FL 32610 0277, USA
    Clin Infect Dis 31:1155-63. 2000
    ..9% and 12.3% vs. 32.1%; P=.004). After day 1, infusional reactions were less frequent with ABLC, but chills/rigors were still higher (21.0% and 24.3% vs. 50.7%; P<.001). Therapeutic success was similar in all 3 groups...
  28. ncbi Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy
    R Yoshikawa
    Second Department of Surgery, Institute for Advanced Medical Sciences Hyogo College of Medicine, Nishinomiya, Japan
    Cancer Res 61:1029-37. 2001
    ..In our clinical trial, we showed efficacy independent of p53 status, ascertained by cell kinetic analysis in vitro, which may lead to a novel concept of schedule-oriented biochemical modulation of this drug...
  29. ncbi Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta
    Y S Lee
    Department of Paediatrics, National University of Singapore, National University Hospital, Singapore
    Eur J Pediatr 160:641-4. 2001
    ..This may represent a net reduction in bone resorption and provides a biochemical explanation for the increase in bone mineralisation. Height standard deviation scores were not affected and there were no significant adverse effects...
  30. ncbi Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients
    J G Slatter
    Pharmacia and Upjohn Company, Kalamazoo, Michigan 49007, USA
    Drug Metab Dispos 28:423-33. 2000
    ..These results show that the parent drug and its three major metabolites account for virtually all CPT-11 disposition, with fecal excretion representing the major elimination pathway...
  31. ncbi Start-up delays of infusion syringe pumps
    T Neff
    Research Group, Department of Intensive Care and Neonatology, University Children's Hospital, Zurich, Switzerland
    Paediatr Anaesth 11:561-5. 2001
    ..CONCLUSIONS: Syringe pump design affects start-up delay times because of free play of the syringe. These delays can be eliminated by a start-up bolus of 2 ml prior to connecting the infusion line to the patient...
  32. ncbi Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin
    Leonard W Seymour
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, United Kingdom
    J Clin Oncol 20:1668-76. 2002
    ..The present phase I study was devised to determine the toxicity, pharmacokinetic profile, and targeting capability of PK2...
  33. ncbi Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine
    H Ulrich-Pur
    Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Vienna, Austria
    Oncology 60:313-5. 2001
    ....
  34. ncbi Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia
    D P Nicolau
    Department of Pharmacy Research, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Int J Antimicrob Agents 17:497-504. 2001
    ....
  35. ncbi Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation
    Michael N Sack
    The Hatter Institute for Cardiology Research, MRC Inter University Cape Heart Group, University of Cape Town Medical School, South Africa
    J Am Coll Cardiol 41:1404-7. 2003
    ....
  36. ncbi Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
    S L C E Buijk
    Department of Surgical Intensive Care, Erasmus University Medical Centre, Rotterdam, The Netherlands
    J Antimicrob Chemother 49:121-8. 2002
    ..60% of the concomitant serum AUCs. In critically ill surgical patients with severe IAIs, CI of ceftazidime resulted in more favourable concentrations in serum and peritoneal exudate than 8-hourly bolus infusion...
  37. ncbi Conservative treatment of postsurgical lymphatic leaks with somatostatin-14
    J M Collard
    Departments of Surgery, St Luc Academic Hospital, Brussels, Belgium
    Chest 117:902-5. 2000
    ....
  38. ncbi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Turin
    J Clin Oncol 20:4285-91. 2002
    ..To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC)...
  39. ncbi Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer
    C J McGinn
    Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 19:4202-8. 2001
    ..The primary objective of this phase I trial was to determine the maximum-tolerated dose of radiation that could be delivered to the primary tumor concurrent with full-dose gemcitabine in patients with advanced pancreatic cancer...
  40. ncbi Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
    J M Meerum Terwogt
    The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Anticancer Drugs 12:315-23. 2001
    ..Consequently, the safety profile may differ significantly from standard paclitaxel...
  41. ncbi Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
    Joyce O'Shaughnessy
    Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    J Clin Oncol 20:2812-23. 2002
    ..This international phase III trial compared efficacy and tolerability of capecitabine/docetaxel therapy with single-agent docetaxel in anthracycline-pretreated patients with MBC...
  42. ncbi Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    Caio M Rocha Lima
    University of Miami and Sylvester Cancer Center, Miami, FL 33162, USA
    J Clin Oncol 22:3776-83. 2004
    ....
  43. ncbi Zoledronic acid and clinical fractures and mortality after hip fracture
    Kenneth W Lyles
    Duke University Medical Center, Durham, NC, USA
    N Engl J Med 357:1799-809. 2007
    ..Mortality is increased after a hip fracture, and strategies that improve outcomes are needed...
  44. ncbi Phase I trial of combretastatin a-4 phosphate with carboplatin
    Joshua H Bilenker
    University of Pennsylvania Cancer Center, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:1527-33. 2005
    ..Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin...
  45. ncbi Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study
    Peter C Thuss-Patience
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Universitatsmedizin Berlin, Campus Virchow Klinkum, Augustenburger Platz 1, 13353 Berlin, Germany
    J Clin Oncol 23:494-501. 2005
    ..A combination of docetaxel and fluorouracil (DF) was evaluated in an outpatient setting and compared with epirubicin, cisplatin, and fluorouracil (ECF), which served as an internal control arm to avoid selection bias...
  46. ncbi Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
    P O'BRIEN
    Trans Tasman Radiation Oncology Group Department of Radiation Oncology, Newcastle Mater Hospital, Newcastle, New South Wales, Australia
    J Clin Oncol 18:519-26. 2000
    ..To assess, in a multi-institutional setting, the impact on relapse, survival, and toxicity of adding two cycles of intravenous methotrexate to cranial irradiation for immunocompetent patients with primary CNS lymphoma...
  47. ncbi Decreased TCA cycle rate in the rat brain after acute 3-NP treatment measured by in vivo 1H-[13C] NMR spectroscopy
    Pierre Gilles Henry
    CEA and UMR CEA CNRS 2210, Service Hospitalier Frederic Joliot, Orsay, France
    J Neurochem 82:857-66. 2002
    ..43 micro mol/g/min in both groups. These results suggest that both Vtca and Vx are altered during 3-NP treatment, and that both glutamate C4 and C3 labelling time courses are necessary to obtain a reliable measurement of Vtca...
  48. ncbi Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo
    Hyo Jeong Kim
    Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, Connecticut 06520 8020, USA
    Diabetes 53:1060-7. 2004
    ..These findings implicate an important role of inflammatory cytokines in the pathogenesis of insulin resistance...
  49. ncbi Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis
    Matthias Lange
    Department of Anesthesiology and Intensive Care, University of Munster, Albert Schweitzer Strasse 33, 48149 Munster, Germany
    Intensive Care Med 34:821-32. 2008
    ..We briefly describe the pathophysiology and pharmacology of septic shock relevant to the treatment with vasopressin analogues. In addition, differences in pharmacokinetics and pharmacodynamics between AVP and TP are discussed...
  50. ncbi Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure
    Noritoshi Nagaya
    Department of Internal Medicine, National Cardiovascular Center, 5 7 1 Fujishirodai, Suita, Osaka 565 8565, Japan
    Circulation 110:3674-9. 2004
    ..We investigated the effects of ghrelin on left ventricular (LV) function, exercise capacity, and muscle wasting in patients with chronic heart failure (CHF)...
  51. ncbi A randomized controlled trial comparing a computer-assisted insulin infusion protocol with a strict and a conventional protocol for glucose control in critically ill patients
    Alexandre B Cavalcanti
    Intensive Care Unit, Hospital Israelita Albert Einstein, São Paulo 05652 000, Brazil
    J Crit Care 24:371-8. 2009
    ..The objective of this study is to evaluate blood glucose (BG) control efficacy and safety of 3 insulin protocols in medical intensive care unit (MICU) patients...
  52. ncbi Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK)
    Christopher S Gray
    School of Clinical Medical Sciences, University of Newcastle, Newcastle upon Tyne, UK
    Lancet Neurol 6:397-406. 2007
    ..We sought to determine whether treatment with glucose-potassium-insulin (GKI) infusions to maintain euglycaemia immediately after the acute event reduces death at 90 days...
  53. ncbi Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers
    Yongqing Wang
    Research Division of Clinical Pharmacology, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China
    Eur J Clin Pharmacol 66:563-9. 2010
    ..To explore the effect of cytochrome P450 2C19 (CYP2C19) polymorphisms on the relationship between the pharmacokinetics and pharmacodynamics of omeprazole administered by intravenous successive infusions in Chinese healthy volunteers...
  54. ncbi Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled tria
    M Boogaerts
    Department of Hematology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Ann Intern Med 135:412-22. 2001
    ..CONCLUSIONS: Itraconazole and amphotericin B have at least equivalent efficacy as empirical antifungal therapy in neutropenic patients with cancer. However, itraconazole is associated with significantly less toxicity...
  55. ncbi Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes
    Rita Basu
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 1st St SW, Room 5 194 Joseph, Rochester, MN 55905, USA
    Diabetes 57:24-31. 2008
    ..To determine mechanisms by which pioglitazone and metformin effect hepatic and extra-hepatic insulin action...
  56. ncbi Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
    R Rosell
    Hospital Germans Trias i Pujol Hospital, Badalona, Spain
    Ann Oncol 13:1539-49. 2002
    ..Survival, toxicity and quality of life were also compared...
  57. ncbi Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities
    Wells A Messersmith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 10:6522-7. 2004
    ....
  58. ncbi Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy
    Danilo Toni
    Unità di Trattamento Neurovascolare, Department of Neurological Sciences, University of Rome La Sapienza, Rome, Italy
    Cerebrovasc Dis 25:129-35. 2008
    ..However, little information exists on its use in elderly patients, in particular those aged >80 years, who at present are excluded from treatment...
  59. ncbi Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer
    Elizabeth A Poplin
    Operations Office, 14980 Omicron Dr, San Antonio, TX 78245 3217, USA
    J Clin Oncol 23:1819-25. 2005
    ....
  60. ncbi Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement
    E Rejon
    Rheumatology Unit, Hospital Valme, Seville, Spain
    Scand J Rheumatol 33:323-6. 2004
    ..To evaluate the clinical response and safety profile of infliximab in refractory ankylosing spondylitis patients...
  61. ncbi Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
    Eric Raymond
    Department of Medicine, Gustave Roussy Institute, Vellefaux, France
    J Clin Oncol 22:2336-47. 2004
    ..To establish the safety, tolerability, and pharmacokinetic parameters of CCI-779, a selective inhibitor of the mammalian target of rapamycin, in patients with advanced cancer...
  62. ncbi Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
    Michele Milella
    Divisions of Medical Oncology A and C, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Cancer 101:133-8. 2004
    ..Cyclooxygenase-2 (COX-2) is up-regulated frequently and may constitute a promising therapeutic target in patients with pancreatic ductal adenocarcinoma (PDAC)...
  63. ncbi Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial
    T S Yang
    Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan
    Ann Oncol 13:1771-8. 2002
    ..We determined the maximum tolerated dose (MTD) and then further evaluated the response rate and safety profile of gemcitabine (Gem) plus doxorubicin (Dox) in chemonaïve patients with advanced hepatocellular carcinoma (HCC)...
  64. ncbi American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
    Bruce E Hillner
    J Clin Oncol 21:4042-57. 2003
    ..To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women...
  65. ncbi The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
    Robert D Arbeit
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Clin Infect Dis 38:1673-81. 2004
    ..0001). The frequency and distribution of adverse events were similar among both treatment groups. Overall, the safety and efficacy of daptomycin were comparable with conventional therapy...
  66. pmc Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats
    Matthias E Liechti
    Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    Eur J Pharmacol 554:164-74. 2007
    ....
  67. ncbi Increasing intravenous infusions of glucose improve body condition but not lactation performance in midlactation dairy cows
    B Al-Trad
    Institute of Veterinary Physiology, University of Leipzig, D 04103 Leipzig, Germany
    J Dairy Sci 92:5645-58. 2009
    ..This may suggest that the metabolic fate of glucose is modified by metabolic signals, hormonal signals, or both from the portal-drained viscera when absorbed from the intestine...
  68. ncbi Management and preparedness for infusion and hypersensitivity reactions
    Heinz Josef Lenz
    University of Southern California, Los Angeles, USA
    Oncologist 12:601-9. 2007
    ..This article reviews the characteristics and management of hypersensitivity reactions to monoclonal antibodies and commonly used chemotherapy agents...
  69. ncbi The use of in-line intravenous filters in sick newborn infants
    R A van Lingen
    Department of Paediatrics Princess Amalia, Isala Clinics, Zwolle, The Netherlands
    Acta Paediatr 93:658-62. 2004
    ..v. lines...
  70. ncbi Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and meta-analysis
    Abdullah A Alghamdi
    Division of Cardiac Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
    J Card Surg 20:293-9. 2005
    ..64 (95% confidence interval = 0.47, 0.87, and p = 0.004)...
  71. pmc Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy
    Anne Schmitt-Hoffmann
    Basilea Pharmaceutica, Ltd, P O Box 3255, 4002 Basel, Switzerland
    Antimicrob Agents Chemother 50:279-85. 2006
    ..The pharmacokinetics of BAL4815 are well suited to maintaining concentrations of BAL4815 for a long period of time in the body and to enabling an effective treatment of systemic mycoses...
  72. ncbi The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial
    Gavin D Perkins
    Department of Intensive Care Medicine, Birmingham Heartlands Hospital, UK
    Am J Respir Crit Care Med 173:281-7. 2006
    ..Experimental data suggest that manipulation of alveolar fluid clearance with beta-agonists can accelerate the resolution of alveolar edema and improve survival...
  73. ncbi Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation
    Tatsuo Furukawa
    Division of Bone Marrow Transplantation, Niigata University Medical and Dental Hospital, Asahimachi Dori 1 754, Chuoku, Niigata, Japan
    Int J Hematol 92:144-51. 2010
    ..To confirm this assumption, a prospective clinical study is required...
  74. ncbi Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors
    M Marty
    , Paris, France
    Ann Oncol 12:1643-9. 2001
    ..Reliable, corresponding doses between oral and i.v. vinorelbine were established, which will result in bioequivalent AUC...
  75. ncbi Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group
    P R Kowey
    Lankenau Hospital and Medical Research Center, Wynnewood, PA 19096, USA
    Circulation 92:3255-63. 1995
    ..Therefore, an intravenous form of therapy is advantageous. This study was designed to compare the safety and efficacy of a high and a low dose of intravenous amiodarone with bretylium, the only approved class III antiarrhythmic agent...
  76. ncbi Transillumination of the palm for venipuncture in infants
    A Goren
    Pediatric Center, Maccabi Health Services, Ramat Hasharon, Israel
    Pediatr Emerg Care 17:130-1. 2001
    ..CONCLUSIONS: Transillumination of the palm can aid in establishing venous access in infants. This can be easily carried out using a common otoscope...
  77. ncbi The control of blood glucose in the critical diabetic patient: a neuro-fuzzy method
    D Dazzi
    Cattedra di Endocrinologia, Dipartimento di Medicina, Universita' di Parma, Parma, Italy
    J Diabetes Complications 15:80-7. 2001
    ..5 mmol/l had never been observed. In conclusion, the neuro-fuzzy control system is effective in improving the BG control in critical diabetic patients without increasing either the number of BG determinations or the risk of hypoglycemia...
  78. ncbi A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK
    D H Smith
    Kaiser Permanente Center for Health Research, Portland, OR 97227 1110, USA
    Ann Oncol 13:1590-7. 2002
    ....
  79. ncbi Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein
    Radjesh J Bisoendial
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
    Circulation 107:2944-8. 2003
    ..In these familial hypoalphalipoproteinemia subjects, we evaluated the impact of isolated low HDL on endothelial function and the vascular effects of an acute increase in HDL...
  80. ncbi Enzyme replacement therapy in Fabry disease: a randomized controlled trial
    R Schiffmann
    Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bldg 10, Room 3D03, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 1260, USA
    JAMA 285:2743-9. 2001
    ..Most patients experience debilitating neuropathic pain and premature mortality because of renal failure, cardiovascular disease, or cerebrovascular disease...
  81. ncbi Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
    M Ducreux
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:467-73. 2004
    ..A randomized phase II, open-label multicenter study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated, advanced pancreatic carcinoma (APC)...
  82. ncbi Sublingual sugar administration as an alternative to intravenous dextrose administration to correct hypoglycemia among children in the tropics
    Hubert Barennes
    Centre Muraz, Bobo Dioulasso, Burkina Faso, France
    Pediatrics 116:e648-53. 2005
    ..A randomized, clinical trial was performed in Burkina Faso among moderately hypoglycemic children, comparing sublingual sugar administration with oral water, oral sugar, and dextrose infusion administrations...
  83. ncbi Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
    ....
  84. ncbi Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans
    Andreas L Birkenfeld
    Franz Volhard Clinical Research Center, Haus 129, Charite Campus Buch, Wiltbergstrasse 50, 13125 Berlin, Germany
    J Clin Endocrinol Metab 90:3622-8. 2005
    ..Atrial natriuretic peptide (ANP) in pharmacological concentrations stimulates lipid mobilization in humans...
  85. ncbi Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats
    Y Uehara
    Second Department of Medicine, University of Tokyo, Bunkyo ku, Japan
    Am J Hypertens 10:83S-88S. 1997
    ....
  86. ncbi Can initial distribution volume of glucose predict hypovolemic hypotension after radical surgery for esophageal cancer?
    A Suzuki
    Department of Anesthesiology, University of Hirosaki School of Medicine, 5 Zaifu cho, Hirosaki Shi, 036 8562, Japan
    Anesth Analg 92:1146-51. 2001
    ..Glucose dilution using glucose 5 g and a one-compartment model can predict it simply and rapidly...
  87. ncbi Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas
    S Kubicka
    Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Hepatogastroenterology 48:783-9. 2001
    ..In contrast, palliative chemotherapy with gemcitabine cannot be recommended in patients with hepatocellular carcinoma and liver cirrhosis...
  88. ncbi A phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer
    A L Thomas
    Department of Oncology, Leicester Royal Infirmary, UK
    Cancer Chemother Pharmacol 48:266-8. 2001
    ..A phase II study was designed to assess the efficacy and safety of Caelyx (liposomal doxorubicin) in patients with advanced or metastatic gastric cancer...
  89. ncbi Mechanism-based pharmacokinetic model for paclitaxel
    A Henningsson
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Sweden
    J Clin Oncol 19:4065-73. 2001
    ..received paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) (135 to 225 mg/m(2)) as 3- or 24-hour intravenous infusions. Seven of the patients received combination therapy with doxorubicin or cisplatin...
  90. ncbi Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer
    Richard L Schilsky
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 20:582-7. 2002
    ..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination...
  91. ncbi Pharmacology of antineoplastic agents in older cancer patients
    Stuart M Lichtman
    Department of Medicine, Don Monti Division of Medical Oncology, North Shore University Hospital, New York University School of Medicine, 300 Community Drive, Manhasset, NY 11030, USA
    Crit Rev Oncol Hematol 46:101-14. 2003
    ..Careful attention to the physiologic changes with age, and dose adjustments necessary for end organ dysfunction (renal, hepatic) are needed to ensure the safe administration of chemotherapy...
  92. pmc Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
    J Edmond Wraith
    Willink Biochemical Genetics Unit, Royal Manchester Children s Hospital, Hospital Road, Manchester M27 4HA, UK
    Eur J Pediatr 167:267-77. 2008
    ..Weekly intravenous infusions of idursulfase have been shown to improve many of the signs and symptoms and overall wellbeing in patients ..
  93. ncbi A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
    M Gore
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Eur J Cancer 38:57-63. 2002
    ..v. formulation, but the clinical significance of this needs to be interpreted in the context of second-line palliative treatment. Oral topotecan is convenient and well tolerated and further studies to clarify its role are ongoing...
  94. ncbi Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, E Campus, Kirstein 158, Boston, MA 02215, USA
    J Clin Oncol 22:909-18. 2004
    ..To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC)...
  95. pmc Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
    J H Bilenker
    Abramson Family Cancer Center, University of Pennsylvania Cancer Center, 51 N 39th St, MAB, Philadelphia, PA 19104, USA
    Br J Cancer 91:213-8. 2004
    ..BMS-184476 in combination with carboplatin was well tolerated at a dose of 50/6 and shows evidence of antitumour activity in a pretreated population...
  96. ncbi Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions
    H Koppler
    Praxis für Hämatologie und Onkologie, Neverstrasse 5, D 56058 Koblenz, Germany
    Onkologie 24:283-5. 2001
    ..v., just prior to paclitaxel has been shown to be equally effective. In an attempt to reduce steroid-induced side effects, especially for patients receiving weekly paclitaxel protocols, we reduced the dexamethasone dose...
  97. ncbi Treatment of a persistent postoperative chylothorax with somatostatin
    P C Rimensberger
    Department of Pediatrics, Hopital des Enfants, University Hospital of Geneva, Switzerland
    Ann Thorac Surg 66:253-4. 1998
    ..Thereafter, continuous somatostatin infusion for 14 days led to the reduction and finally cessation of chyle production. This treatment allowed early enteral feeding and avoided further surgical intervention...
  98. ncbi Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations
    J W Mouton
    Department of Clinical Microbiology, Erasmus University Hospital Rotterdam, The Netherlands
    J Antimicrob Chemother 38:5-15. 1996
    ....
  99. ncbi NXY-059 for acute ischemic stroke
    Kennedy R Lees
    Acute Stroke Unit and Cerebrovascular Clinic, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, United Kingdom
    N Engl J Med 354:588-600. 2006
    ..NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke...
  100. ncbi Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days
    Weijing Sun
    Abrahmson Family Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:5221-7. 2003
    ..2 +/- 4.5 h, respectively. BMS-184476 60 at mg/m(2) with cisplatin at 75 mg/m(2) with appropriate supportive therapy is the dose recommended for further evaluation...
  101. ncbi Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer
    C H Kohne
    Department of Haematology Oncology and Tumor Immunology, Robert Rossle Klinik, Berlin, Germany
    J Clin Oncol 16:418-26. 1998
    ..To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer...

Research Grants63

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Each cycle will involve two separate intravenous infusions of rituximab given 2 weeks apart...
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Each cycle will involve two separate intravenous infusions of rituximab given 2 weeks apart...
  3. Phase 2a Study of Ataluren in Hemophilia A and B (IND 104,321)
    JAY A BARTH; Fiscal Year: 2010
    ..phenotype while sparing them the substantial risks, inconvenience, and expense associated with frequent intravenous infusions of FVIII/FIX concentrate...
  4. Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency
    Jeffrey D Chulay; Fiscal Year: 2013
    ..The only currently approved therapy for this orphan disease is weekly intravenous infusions of AAT protein that has been purified from normal plasma donors...
  5. Hematopoietic gene therapy for hemophilia A
    H Trent Spencer; Fiscal Year: 2013
    ..State of the art treatment for hemophilia A consists of frequent intravenous infusions of fVIII containing products...
  6. Fatty acid sources of fructose and HFCS-induced postprandial hypertriglyceridemia
    Jean Marc Schwarz; Fiscal Year: 2013
    ..Stable isotopes will be administered (via oral consumption and 26-h intravenous infusions) to subsets of subjects during the 24-h serial blood sampling protocols that are conducted in all study ..
  7. Novel Therapies for Chronic Renal Allograft Dysfunction in Children
    William E Harmon; Fiscal Year: 2012
    ..Since belatacept is provided as once monthly intravenous infusions, the protocol has the added potential to improve immunosuppression adherence in adolescent transplant...
  8. NMR Studies of Brain Energetics & Hypoglycemia In Vivo
    Kevin Behar; Fiscal Year: 2009
    ..the application of state-of-the-art In Vivo Magnetic Resonance Spectroscopy (MRS) in conjunction with intravenous infusions of 13C-labeled substrates...
  9. RENAL FUNCTION AND BLOOD PRESSURE CONTROL IN PREGNANCY
    Edmond Quillen; Fiscal Year: 2000
    ..This will be tested with intrarenal infusions of ANF challenged with intrarenal and intravenous infusions of the nitric oxide synthase inhibitor L-NAME to permit evaluation of purported direct and indirect, ..
  10. Metabolism of Endothelial Dysfunction in Renal Disease
    Leticia Castillo; Fiscal Year: 2006
    ..cysteine oxidation and the rates of synthesis of whole blood glutathione, by conducting primed, constant intravenous infusions of the stable isotope tracers L4guanidino 15N2] arginine, L-2H3-methyl]methionine and L- I) 3C]methionine;..
  11. ECHOCARDIOGRAPHIC ASSESSMENT OF MICROVASCULAR PERFUSION
    Kevin Wei; Fiscal Year: 2003
    ..Using both intracoronary injections, and continuous intravenous infusions of micro-bubbles, MCE also has the ability to discriminate between extramyocardial and capillary sites of ..
  12. Diaphragm Fatigue Prevention in Emphysema
    NANCY SMITH BLAIR; Fiscal Year: 2006
    ..is to determine if exercise conditioning and pharmacological improvement of diaphragm muscle function with intravenous infusions of dobutamine (DOB) are effective in abating the development of DF in EMP...
  13. NUCLEUS ACCUMBENS INVOLVEMENT IN COCAINE REINFORCEMENT
    GREGORY MARK; Fiscal Year: 2002
    ..Rats will be trained to lever-press for intravenous infusions of cocaine on a progressive ratio schedule of reinforcement...
  14. In Vivo Metabolism of Pulmonary Surfactant in Infants
    Aaron Hamvas; Fiscal Year: 2005
    ..Exogenous surfactant enriched with 2H4-choline labeled phosphatidylcholine and intravenous infusions of surfactant phospholipid precursors (administered as U-13C6]glucose, 7,7,8,8-2H4-palmitate, or 1-..
  15. PHARMACODYNAMICS OF ANTILEUKEMIC AGENTS IN CHILDREN
    ALEXANDER SPARREBOOM; Fiscal Year: 2007
    ..Furthermore, medical economics have prompted the use of short intravenous infusions of HDMTX (e.g...
  16. 2001 Workshop on Gene Therapies for Hemophilia
    Inder Verma; Fiscal Year: 2001
    ..While treatment is effective for many people with hemophilia, it consists of life-long, intravenous infusions with clotting factor administered during or after a bleeding event...
  17. NHF Fifth Workshop on Gene Therapies for Hemophilia
    Inder Verma; Fiscal Year: 2002
    ..While treatment is effective for many people with hemophilia, it consists of life-long, intravenous infusions with clotting factor administered during or after a bleeding event...
  18. THIRD WORKSHOP ON GENE THERAPIES FOR HEMOPHILIA
    Inder Verma; Fiscal Year: 2000
    ..While treatment is effective for many people with hemophilia, it consists of life-long, intravenous infusions with clotting factor administered during or after a bleeding event...
  19. CLINICAL PHARMACOLOGY OF INTRATHECAL METHOTREXATE
    W Bleyer; Fiscal Year: 1980
    ..will include evaluation of a variety of conditions on cerebrospinal-fluid methotrexate concentration: intravenous infusions of high-dose methotrexate, cranial irradiation, systemic and intrathecal probenicid administration, body ..
  20. Precursor Preference in Surfactant Synthesis of Newborns
    Kimberly Spence; Fiscal Year: 2004
    ..We will use intravenous infusions of surfactant phospholipid precursors ( [1,2,3,4-13C4] palmitate and [1-13C1] acetate) and gas ..
  21. COCAINE PHARMACOKINETICS AND PHARMACODYNAMICS
    Reese Jones; Fiscal Year: 1990
    ..Dose dependent kinetic differences will be explored after both single dose and intravenous infusions under steady state conditions...
  22. CHOLINERGIC AND OPIATE MECHANISMS IN DRUG REINFORCEMENT
    Shafiqur Rahman; Fiscal Year: 2002
    ..preclinical research uses techniques in which animals are trained to do work (press a lever) to obtain intravenous infusions of nicotine or cocaine...
  23. Determinants of Atherosclerotic Plaque Progression
    Stanley Hazen; Fiscal Year: 2004
    ..b>Intravenous infusions of a form of apolipoprotein (apo) A-I in subjects elicited significant regression of coronary artery ..
  24. EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIV
    DEBORAH LEWINSOHN; Fiscal Year: 2002
    ..T- helper function could potentially be restored by intravenous infusions of IL-2, or by the transfer of autologous HIV-specific CD4+ T helper (Th) clones...
  25. Regulation of Postprandial satiety by cytokines
    ANDREW THAW; Fiscal Year: 2001
    ..Following the establishment of baseline meal patterns for a powdered food diet in 16 rats, intravenous infusions of interleukin- 1B, interleukin-6, or tumor necrosis factor A will be administered at the end of the first ..
  26. Development of Oral Suberoylanilide Hydroxamic Acid
    William Kelly; Fiscal Year: 2003
    ..Initial studies in humans using daily intravenous infusions of SAHA for up to 3 consecutive weeks have shown hat SAHA is safe; there is an accumulation of acetylated ..
  27. EFFECT OF IV INFUSIONS ON ENERGY BALANCE
    HENRY KOOPMANS; Fiscal Year: 1990
    ..The first specific aim is to assess the effect of intravenous infusions of glucose and amino acids and of medical fat emulsions on voluntary food intake and metabolic rate...
  28. Decision Making in End-Stage Heart Failure
    Paul Hauptman; Fiscal Year: 2006
    ..unreadable] [unreadable] The first is designed to examine the use of chronic continuous outpatient intravenous infusions of inotropic drugs, a therapy associated with high costs, unproven clinical efficacy and the potential to ..
  29. Ninth Workshop on Novel Technologies and Gene Transfer for Hemophilia
    Glenn Pierce; Fiscal Year: 2007
    ..While treatment is effective for many people with hemophilia, it consists of life-long, intravenous infusions with clotting factor administered during or after a bleeding event...
  30. Pharmacophore-Modeled Screening for HbF-Inducing Agents
    Susan Perrine; Fiscal Year: 2004
    ..However, the available SCFA drugs require high doses or intravenous infusions, which are difficult for many patients to tolerate...
  31. Mechanistic bases for age-related androgen deficiency
    Johannes Veldhuis; Fiscal Year: 2007
    ..Knowing why testosterone falls should help foster new and safer ways to prevent the problem. [unreadable] [unreadable] [unreadable]..
  32. Ensemble Disruption of the GnRH-LH-Testosterone Axis
    Johannes Veldhuis; Fiscal Year: 2007
    ..Expected corollary outcomes are enhanced diagnosis, assessment and management of more subtle pathophysiology of the male gonadal axis in puberty and adulthood. ..
  33. THE AGING GH AXIS IN POSTMENOPAUSAL WOMEN
    Johannes Veldhuis; Fiscal Year: 2005
    ..An enhanced knowledge base should aid ultimately in formulating more innovative preventive and interventional strategies to limit hyposomatotropism in older and/or estrogen-deficient humans. ..
  34. Novel Active Repressor Model of Human LDL-Receptor Regulation
    Johannes Veldhuis; Fiscal Year: 2008
    ..This would represent a new treatment approach for patients with atherosclerotic disease. [unreadable] [unreadable] [unreadable] [unreadable]..
  35. Analytical Reconstruction of Feedback Signaling in Aging Men
    Johannes Veldhuis; Fiscal Year: 2008
    ..The present proposal develops a general biomathematical framework for dissecting otherwise observed pathways that control hormone output in aging, stress and disease. [unreadable] [unreadable] [unreadable]..
  36. ENSEMBLE MODEL OF STRESS ACTH-ADRENAL AXIS
    Johannes Veldhuis; Fiscal Year: 2005
    ....
  37. ACTIONS OF ESTROGEN IN MATURING GRAAFIAN FOLLICLES
    Johannes Veldhuis; Fiscal Year: 2005
    ..Understanding such fundamental interactions is important to the rational design of alternative strategies to interrupt normal and rescue impaired steroidogenesis in the maturing Graafian follicle and corpus luteum. ..
  38. Neurochemical Correlates of Pathology in Spinocerebellar Ataxias
    GULIN OZ; Fiscal Year: 2008
    ..Successful application of such treatments is expected to reduce the burden caused by these diseases on individuals, their families and society. [unreadable] [unreadable] [unreadable]..
  39. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  40. IKKBeta Mediated Impairment of Endothelial Nitric Oxide Production
    Francis Kim; Fiscal Year: 2010
    ..Aim 3. To determine whether the Toll Like Receptor pathway is necessary for endothelial activation of IKKbeta during the development of vascular insulin resistance. ..
  41. INSULIN RECEPTOR SUBSTRATE -1 AND FLUID SHEAR STRESS
    Francis Kim; Fiscal Year: 2005
    ..To further characterize this potential link between insulin and NO signaling. Specific Aim 3: Characterize FSS dependent signaling elements which associate with IRS-1...
  42. ENHANCED THERAPY RESPONSE IN OSTEOSARCOMA
    GENE DIRESTA; Fiscal Year: 2001
    ..The MSKCC Therapeutics faculty believes that the ALS, if successful in this model, has promise as an adjunct for limb salvage procedures and in the treatment of many unresectable or disfiguring tumors. ..
  43. Diphtheria fusion protein therapy of AML
    ARTHUR FRANKEL; Fiscal Year: 2006
    ..We initiated a phase I single-arm, inter-patient dose escalation clinical trial of five daily intravenous infusions for patients with relapsed or refractory AML...
  44. Functional measure of 3rd trimester FASD: neonatal sheep
    TIMOTHY CUDD; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  45. Targeting protein synthesis in AML
    ARTHUR FRANKEL; Fiscal Year: 2006
    ..These studies will hopefully lead to the design of pivotal phase II and III clinical trials which will define the role of DT388IL3 in the management of AML. ..
  46. CYCLIC AMP/ADENOSINE PATHWAY
    Edwin Jackson; Fiscal Year: 2002
    ..abstract_text> ..
  47. Combination fusion toxin and cytarabine therapy of AML
    ARTHUR FRANKEL; Fiscal Year: 2002
    ..We anticipate these studies should provide the basis for the design and implementation of pivotal multi-institutional phase II and III trials of DTGM/cytarabine therapy for relapsed/refractory AML. ..
  48. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
    ..abstract_text> ..
  49. OPTIMAL PREHOSPITAL CARE OF CHILDHOOD CARDIAC ARREST
    Ian Stiell; Fiscal Year: 2004
    ..The PIs propose to conduct a large feasibility review in five urban areas and to conduct four study planning workshops. ..
  50. DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS
    HEINZ LENZ; Fiscal Year: 2002
    ....
  51. DETERMINING THE GENETICS OF RESTLESS LEGS SYNDROME
    Christopher Earley; Fiscal Year: 2003
    ....
  52. STUDY OF DEXAMETHASONE IN NEONATAL LUPUS CHB
    Jill Buyon; Fiscal Year: 2004
    ....
  53. PROSPECTIVE STUDY OF PANCREATIC CANCER PATHOGENESIS
    Charles Fuchs; Fiscal Year: 2004
    ..These studies will enhance our understanding of pancreatic carcinogenesis and provide a scientific foundation for future preventive efforts. This is the first R01 submitted by the principal investigator following a K award from NCI. ..
  54. Interventional Management of Stroke III Planning Grant
    Joseph Broderick; Fiscal Year: 2004
    ..10. Explore funding of interventional angiography by CMS. 11. Continue interaction with industry, with attention to devices that might be applied to a device-augmented future IV/IA paradigm. ..
  55. Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency
    KERRIE MOREAU; Fiscal Year: 2010
    ..The results should provide new insight into the integrative biological mechanisms by which sex hormone deficiency modulates the age-related reduction in large artery compliance in women as they transition through the menopause. ..
  56. Oxidized Linoleic Acid, Aldosterone, and Obesity
    THEODORE GOODFRIEND; Fiscal Year: 2007
    ..abstract_text> ..
  57. Prenatal Cocaine Exposure: Studies of Brain Function
    Linda Mayes; Fiscal Year: 2008
    ..C. Mayes). [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  58. OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo
    BRUCE SANDS; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  59. Validation of rat models for resistant epilepsy therapy
    Wolfgang Loscher; Fiscal Year: 2005
    ..Our goal is to establish standard assays that can be employed by researchers to continue the search for treatments of drug resistant epilepsy. ..
  60. Reward-Motivated Learning in Adolescent Cannabis Users
    Leslie Jacobsen; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  61. Transitional States in Drug Addiction
    Leonard Howell; Fiscal Year: 2007
    ..These integrated efforts, including behavioral and mechanistic approaches, will provide a comprehensive analysis to elucidate transitional states in cocaine addiction. [unreadable] [unreadable]..
  62. PET IMAGING AND COCAINE NEUROPHARMACOLOGY IN MONKEYS
    Leonard Howell; Fiscal Year: 2006
    ..The results obtained will also evaluate the effectiveness of monoamine transporters as potential targets for cocaine medications development. ..
  63. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert A Knight; Fiscal Year: 2010
    ..e., BBB opening) and both will be functions of the variations in BBB associated proteins and/or brain swelling;and 2) the size of these changes are correlated over time, ROI, and treatment. ..